Phase II
Increasing achievement of FSGS partial remission of proteinuria and stable eGFR observed out to 84 weeks in open-label extension
At the 11th Clinical Trials in Alzheimer’s Disease Conference
DUET publication highlighted during Best of ASN Journals session at ASN Kidney Week 2018
Cristal Therapeutic announced today the first patient has been dosed in its Phase 2 clinical trial of lead nanomedicine candidate CPC634 for patients with platinum-resistant ovarian cancer.
Initial data from the first cohort expected in first half of 2019
The United Kingdom is calling for greater clinical trial transparency after a government committee released a report that indicates that data from about half of all clinical trials in that country are not published, raising concerns over research integrity and risks to human health.
There are no treatments for autism, but that’s not stopping research into the development of therapies for core symptoms of autism spectrum disorder. This week, London-based AMO Pharma reported Phase II results from its investigational glycogen synthase kinase 3 (GSK3) beta inhibitor, AMO-02 (tideglusib).
Santhera Pharmaceuticals announces the start of a Phase Ib/IIa multiple ascending dose (MAD) trial with POL6014 in patients with cystic fibrosis (CF).
Roche announced positive data from its Phase II STAIRWAY clinical trial. The trial evaluated the extended durability of faricimab (RG7716) in the treatment of neovascular (wet) age-related macular degeneration (nAMD).
Routine corticosteroid treatment correlates with increased mortality and decreased Traumakine efficacy
PRESS RELEASES